Multifunctional pluronic/poly(ethylenimine) nanoparticles for anticancer drug.

Area of Science:

• Materials Science
• Nanotechnology
• Pharmaceutical Sciences

Background:

• Developing effective drug delivery systems is crucial for cancer chemotherapy.
• Nanoparticles offer potential for targeted drug delivery and reduced side effects.
• Improving nanoparticle targeting can enhance therapeutic efficacy in tumors.

Purpose of the Study:

• To develop and characterize folate-conjugated nanoparticles for enhanced Paclitaxel (PTX) delivery.
• To evaluate the drug loading, release kinetics, and in vitro cytotoxicity of the targeted nanoparticles.
• To assess the potential of these nanoparticles in improving tumor specificity and reducing chemotherapy side effects.

Main Methods:

• Preparation of cross-linked cationic polymer nanoparticles using Pluronic F127 and poly(ethylenimine) (PEI).
• Conjugation of folic acid (folate) to the nanoparticle surface for enhanced targeting.
• Characterization using FT-IR, Dynamic Light Scattering (DLS), and Transmission Electron Microscopy (TEM).
• In vitro drug release studies and cytotoxicity assays against cancer cells.

Main Results:

• Folate conjugation increased the drug-loading content of Paclitaxel (PTX) in nanoparticles.
• PTX-loaded nanoparticles exhibited sustained release profiles, superior to free PTX solution.
• Folate-modified nanoparticles demonstrated significantly higher in vitro cytotoxicity against cancer cells compared to free PTX.
• Targeted nanoparticles showed enhanced efficacy due to folate receptor overexpression in tumors.

Conclusions:

• Folate-conjugated PEI/Pluronic F127 nanoparticles are effective carriers for Paclitaxel (PTX).
• This targeted drug delivery system enhances tumor specificity and reduces systemic toxicity.
• The developed nanoparticles represent a promising strategy for improving cancer chemotherapy outcomes.